Lapatinib and Bevacizumab for Metastatic Breast Cancer

Inclusion criteria: * Females that are at least 18 years of age. * Women of childbearing potential must have a negative serum pregnancy test at screening. * Documented evidence of HER2-overexpressing unresectable or metastatic breast cancer. Disease may/may not have been treated in metastatic setting. * Subjects are permitted (but not required) to have previously-treated brain metastases that are stable and asymptomatic. * Adequate hepatic, renal and cardiac function * ECOG score 0-1 and a life expectancy of at least 12 weeks. * Able to swallow oral medication * Signed informed consent Exclusion criteria: * Pregnancy * Unstable or symptomatic CNS metastases * Major surgery within 28 days of enrollment (minor surgery within 7 days). * Prior anti-cancer treatment within 14 days of enrollment, or unresolved treatment-related toxicities. * A serious non-healing wound, ulcer, or bone fracture at baseline. * Class II, III or IV heart failure as defined by the NYHA functional classification system * History of significant vascular disease, arterial thrombosis, unstable INR, hypertensive crisis, or uncontrolled hypertension. * History of myocardial infarction, stenting procedure, or angioplasty within 6 months of enrollment. * History of abdominal fistulae, gastrointestinal perforation, or intra-abdominal abscess within 6 months of enrollment. * History of malabsorption syndrome, ulcerative colitis, or bowel obstruction. * Proteinuria * Requires concurrent anti-cancer treatment or…